Daisy M A E Jonkers Selected Research

peppermint oil

11/2021	A trial-based economic evaluation of peppermint oil for the treatment of irritable bowel syndrome.
1/2020	Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
11/2018	A Novel Ileocolonic Release Peppermint Oil Capsule for Treatment of Irritable Bowel Syndrome: A Phase I Study in Healthy Volunteers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daisy M A E Jonkers Research Topics

Disease

6	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 12/2021 - 01/2016
4	Abdominal Pain (Pain, Abdominal) 05/2022 - 11/2018
3	Inflammation (Inflammations) 05/2022 - 12/2010
3	Colorectal Neoplasms (Colorectal Cancer) 03/2012 - 06/2009
3	Adenoma (Adenomas) 03/2012 - 06/2009
2	Crohn Disease (Crohn's Disease) 11/2020 - 10/2016
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2018 - 01/2012
2	Fibrosis (Cirrhosis) 01/2014 - 11/2013
2	Neoplasms (Cancer) 03/2012 - 07/2009
2	Ulcerative Colitis 12/2010 - 09/2010
1	Depressive Disorder (Melancholia) 12/2021
1	Anxiety Disorders (Anxiety Disorder) 12/2021
1	Visceral Pain 01/2021
1	Metabolic Diseases (Metabolic Disease) 01/2019
1	Cysts 01/2019
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 12/2018
1	Fistula 05/2017
1	Microscopic Colitis 01/2017
1	Celiac Disease (Celiac Sprue) 01/2017
1	Rheumatoid Arthritis 01/2017
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2016
1	Frailty 01/2016
1	Obesity 01/2014
1	Liver Diseases (Liver Disease) 11/2013
1	Type 2 Diabetes Mellitus (MODY) 01/2012
1	Diarrhea 01/2008

Drug/Important Bio-Agent (IBA)

6	Biomarkers (Surrogate Marker)IBA 10/2016 - 06/2009
3	peppermint oilIBA 11/2021 - 11/2018
2	Immunologic Factors (Immunomodulators)IBA 01/2018 - 05/2017
2	Biological ProductsIBA 01/2018 - 05/2017
2	Proteins (Proteins, Gene)FDA Link 01/2014 - 07/2009
2	Butyrates (Butyrate)IBA 12/2010 - 09/2010
2	DNA (Deoxyribonucleic Acid)IBA 07/2009 - 06/2009
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 05/2022
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 12/2021
1	AnkyrinsIBA 01/2021
1	Pharmaceutical PreparationsIBA 11/2020
1	Indicators and Reagents (Reagents)IBA 11/2020
1	Volatile Fatty AcidsIBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	pyrazolanthroneIBA 01/2019
1	Adalimumab (Humira)FDA Link 01/2019
1	Virulence Factors (Pathogenicity Factors)IBA 12/2018
1	Capsules (Microcapsules)IBA 11/2018
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018
1	Proton Pump InhibitorsIBA 01/2017
1	AntigensIBA 01/2017
1	Tobacco Smoke Pollution (Passive Smoking)IBA 01/2017
1	Volatile Organic CompoundsIBA 01/2016
1	CarbohydratesIBA 01/2014
1	ErythritolIBA 01/2014
1	Lactulose (Duphalac)FDA LinkGeneric 01/2014
1	RhamnoseIBA 01/2014
1	Sucrose (Saccharose)IBA 01/2014
1	trichlorosucrose (sucralose)IBA 01/2014
1	EndotoxinsIBA 11/2013
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 03/2012
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2012
1	Hemoglobins (Hemoglobin)IBA 10/2011
1	AntioxidantsIBA 12/2010
1	Butyric Acid (Butanoic Acid)IBA 12/2010
1	Glutathione (Reduced Glutathione)IBA 12/2010
1	Messenger RNA (mRNA)IBA 07/2009
1	hydrogen sulfite (bisulfite)IBA 07/2009
1	Calcibiotic Root Canal SealerIBA 06/2009
1	tissue-factor-pathway inhibitor 2 (PP5)IBA 06/2009
1	Amoxicillin (Wymox)FDA LinkGeneric 01/2008
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2008

Therapy/Procedure

2	Enema (Enemas) 12/2010 - 09/2010
1	Biological Therapy 05/2017
1	Polypharmacy 01/2016
1	Therapeutics 01/2008